Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward
- PMID: 32502436
- DOI: 10.1016/S1470-2045(20)30211-4
Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward
Comment on
-
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X. Lancet Oncol. 2020. PMID: 32502443 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical